The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: A CTF study

Gynecologic Oncology

Volumn 63, Issue 2, 1996, Pages 234-237

  Gadducci, Angiolo ^a   Landoni, Fabio ^b   Maggino, Tiziano ^c   Sartori, Enrico ^d   Zola, Paolo ^e   Fanucchi, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030298466     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0312     Document Type: Article

References (22)

1. 1. Bast, R. C., Jr., Klug, T. L., Schaetzl, E., Lavin, P., Niloff, J. M., Greber, T. F., Zurawski, Vr., Jr., and Knapp, R. C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19.9 and carcinoembryonic antigen, Am. J. Obstet. Gynecol. 149, 553-559 (1984).
2. 2. Fioretti, P., Gadducci, A., Ferdeghini, M., Bartolini, T., Bianchi, R., and Facchini, V. Correlation of CA 125 and CA 19.9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma, Gynecol. Oncol. 28, 278-283 (1987).
3. 3. Schilthuis, M. S., Aalders, J. G., Bouma, J., Khooi, H., Fleuren, G. J., Willemse, P. H. B., and De Bruijn, H. W. A. Serum CA 125 levels in epithelial ovarian cancer: Relation with findings at second-look operations and their role in the detection of tumour recurrence, Br. J. Obstet. Gynaecol. 94, 202-207 (1987).
4. 4. Jacobs, I., and Bast, R. C., Jr. The CA 125 tumour-associated antigen: A review of the literature, Hum. Reprod. 4, 1-12 (1989).
5. 5. Fioretti, P., Gadducci, A., Ferdeghini, M., Prontera, C., Malagnino, G., Facchini, V., Mariani, G., and Bianchi, R. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients, Gynecol. Oncol. 44, 155-160 (1992).
6. 6. Rustin, G. J. S., van der Burg, M. E. L., and Berek, J. S. Tumor markers, Ann. Oncol. 4(Suppl. 4), 71-77 (1993).
7. 7. van der Burg, M. E. L., Lammes, F. B., van Putten, W. L. J., and Stoter G. Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy, Gynecol. Oncol. 30, 307-312 (1988).
8. 8. Hawkins, R. E., Roberts, K., Wiltshaw, E., Mundy, J., Fryatt, I. J., and McCready, V. R. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma, Br. J. Obstet. Gynaecol. 96, 1395-1399 (1989).
9. 9. Hunter, V. J., Daly, L., Helms, M., Soper, G. T., Berchuck, A., Clarke-Pearson, D. L., and Bast, R. C., Jr. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction, Am. J. Obstet. Gynecol. 163, 1164-1167 (1990).
10. 10. Hogberg, T., and Kagedal, B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma, Acta Obstet. Gynecol. Scand. 69, 423-429 (1990).
11. 11. Buller, R. E., Berman, M. L., Bloss, J. D., Manetta, A., and DiSaia, P. J. Serum CA 125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survival, Gynecol. Oncol. 47, 87-92 (1992).
12. 12. Rosman, M., Hayden, C. L., Thiel, R. P., Chambers, J. T., Kohorn, E. I., Chambers, S. K., and Schwartz, P. E. Prognostic indicators for poor risk epithelial ovarian carcinoma, Cancer 74, 1323-1328 (1994).
13. 13. Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., and Cristofani, R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: Results of a multicentric Italian study, Gynecol. Oncol. 58, 42-47 (1995).
14. 14. Rosen, A., Sevelda, P., Klein, M., Spona, J., and Beck, A. A CA 125 score as a prognostic index in patients with ovarian cancer, Arch. Gynecol. Obstet. 247, 125-129 (1990).
15. 15. Cruickshank, D. J. CA 125 parameters in survivors and nonsurvivors with epithelial ovarian cancer, Int. J. Gynecol. Cancer 1, 279-284 (1991).
16. 16. Brand, E., and Lidor, Y. The decline of CA 125 level after surgery reflects the size of residual ovarian cancer, Obstet. Gynecol. 81, 29-32 (1993).
17. 17. Yedema, C., Kenemans, P., Thomas, C., Massuger, L., Wobbes, Th., Verstraeten, A., Van Kamp, G., and Hilgers, J. CA 125 serum levels in the early post-operative period do not reflect tumor reduction obtained by cytoreductive surgery, Eur. J. Cancer 29, 966-971 (1993).
18. 18. Kabawat, S. E., Bast, R. C., Jr., Bhan, A. K., Welch, W. R., Knapp, R. C., and Colvin, R. B. Tissue distribution of a coelomic-epithelium related antigen recognized by the monoclonal antibody OC125, Int. J. Gynecol. Pathol. 2, 275-285 (1983).
19. 19. Redman, C. W. E., Jones, S. R., Luesly, D. M., Nicholl, S. E., Kelly, K., Buxton, E. J., Chan, K. K., and Blackledge, G. R. P. Peritoneal trauma releases CA 125? Br. J. Cancer 58, 502-504 (1988).
20. 20. Talbot, R. W., Jacobsen, D. J., Nagorney, D. M., Malkasian, G. D., and Ritts, R. E. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer, Surg. Gynecol. Obstet. 168, 407-412 (1989).
21. 21. Van der Zee, A. G. J., Duk, J. M., Aalders, J. G., Boontje, A. H., Ten Hoor, K. A., and De Bruijn, H. W. A. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125, Br. J. Obstet. Gynaecol. 97, 934-938 (1990).
22. 22. Buller, R. E., Berman, M. L., Bloss, J. D., Manetta, A., and DiSaia, P. J. CA 125 regression: A model for epithelial ovarian cancer response, Am. J. Obstet. Gynecol. 165, 360-367 (1991).